跳至主要内容
临床试验/NCT04941053
NCT04941053已完成不适用

Seroprevalence of COVID19 in Sohag Governorate Egypt

Sohag University1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2021年6月3日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
300
试验地点
1
主要终点
seroprevalnce

研究概览

简要总结

Coronavirus disease pandemic has been started in late 2019. Since this date, the number of cases has been increased reaching 32.7 million cases worldwide in 27 September, 2020. . Herd immunity is achieved when enough people become immune to a virus to stop its spread. Around 70% to 90% of a population needs to be immune to protect the uninfected. In A Spanish study of more than 30,000 people estimates that around just 5% of the Spanish population has developed antibodies

详细描述

Aims of work:

A cross-sectional study to detect the seroprevalence to COVID 19 in chronic hemodialysis patients and compare it with the COVID 19 seroprevalence in healthy control in Sohag governorate Egypt

Methods:

After taken informed consent according to Sohag University Ethical Committee A questionnaire on coronavirus symptoms will be asked including epidemiological characters and history of previous COVID 19 infection and infection control measures to prevent it

5 ml of the blood sample will be taken for IgG antibodies testing with a chemiluminescent microparticle immunoassay.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Cross Sectional

入排标准

性别
All
接受健康志愿者

入选标准

  • patient accept to participate

排除标准

  • vaccinated people

结局指标

主要结局

seroprevalnce

时间窗: 3-6-2021 to 30-8-2021

antibody measurement

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Noha Saber Shafik

lecturer

Sohag University

研究点 (1)

Loading locations...

相似试验

Seroprevalence of COVID-19 | 临床试验